Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open-Label Phase 1 Multiple Ascending Dose and Food Effect Study. (2020)

Peer-Reviewed Study · Bach T, Galbiati S, Kennedy JK, Deye G, Nomicos EYH, Codd EE, Garcia HH, Horton J, Gilman RH, Gonzalez AE, Winokur P, An G · 2020

Bach T et al., 2020: Open-label phase 1 multiple ascending dose and food effect study of oxfendazole in healthy adults. A fatty breakfast raised oxfendazole Cmax by 49.2% and AUC by 86.4% and delayed Tmax by about 6.9 h.

Food delayed the oxfendazole Tmax by a median of 6.88 h and resulted in a 49.2% increase in the maximum observed drug concentration in plasma (Cmax) and an 86.4% increase in the area under the concentration-time curve (AUC).

Bach T et al., 2020: Open-label phase 1 multiple ascending dose and food effect study of oxfendazole in healthy adults. A fatty breakfast raised oxfendazole Cmax by 49.2% and AUC by 86.4% and delayed Tmax by about 6.9 h. Phase 1, open-label, multiple ascending dose plus food-effect study; N=36 healthy adults; United States (University of Iowa); oxfendazole oral suspension 3, 7.5 and 15 mg/kg once daily for 5 days, plus a single 3 mg/kg dose fasted versus after a fatty breakfast; NCT03035760. Funder: NIAID/NIH and NCATS. Declared conflicts: none in the PubMed record. Product: oxfendazole oral suspension, manufacturer not named in the abstract. Comparator: fasting versus fed within subject; no placebo arm in the food-effect part. Human oxfendazole data, not fenbendazole.